Parenteral systemic antifungal drugs and their clinical drug informations

Invasive fungal infections are an important cause of morbidity and mortality, especially in with patients’ immune-compromised conditions such as AIDS, cancer, diabetes and burn patients, neonates, organ transplant patients. Therefore, treatment of fungal infections is still a major problem. The drugs used to treat these infections are very limited due to toxicity or inappropriate pharmacokinetic properties. Nowadays, there are three molecules class used in the clinical for these infections: polyenes, azoles and echinocandins. Amphotericin B and lipid formulations have been used for a long time in the treatment of these infections. The development of new triazole derivatives has provided different treatment options (fluconazole, voriconazole and posaconazole). In addition, three echinocandin derivatives (caspofungin, micafungin, and anidulafungin) have been approved for use in medication. The broad-spectrum triazoles and echinocandin derivative drugs have offer more effective and less toxic alternatives to antifungal therapy. This review provides a brief of the pharmacologic principles and clinical usage involved in treatment of systemic fungal infections.

___

Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998;26:781-803.

Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine. 1999;78:123-38.

Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis. 2000;30:662-78.

Georgopapadakou NH, Tkacz JS. The fungal cell wall as a drug target. Trends Microbiol. 1995;3:98-104.

Kathiravan MK, Salake AB, Chothe AS, et al. The biology and chemistry of antifungal agents. Bioorgan Med Chem. 2013;21:1367.

Vandeputte P, Ferrari S, Coste AT. Antifungal resistance and new strategies to control fungal infections. Int J Microbiol. 2012;2012:713687.

Arendrup MC. Epidemiology of invasive candidiasis. Curr Opin Crit Care. 2010;16:445-52

Diekema D, Arbefeville S, Boyken L, et al. The changing epidemiology of healthcare-associated candidemia over three decades. Diagn Micr Infec Dis. 2012;73:45-8.

Katzung BG, Trevor AJ. Antifungal agents. In: Pharmacology. 12th edition. McGraw-Hill,New York; 2006. p. 849-59

Lemke TL, Zito SW, Roche VF, et al. Essentials of Foye’s principles of medicinal chemistry. In: Antifungal agents. 8th edition. Wolters Kluwer, Philadelphia; 2017. p. 478-90.

Raffa RB, Rawls SM. Netter’s Illustrated Pharmacology. In; Fungal infections, Antifungal drugs. 1st edition. Icon Learning Systems, New Jersey; 2013. p. 324-26.

Bharathisha BS, Prasanna S, Puranik SB, et al. Antifungal pharmacology: A review. Research & Reviews: J Pharm Nanotechnol. 2014;2:5-11.

Medscape drug reference. https://search.medscape.com access date 10.07.2018

Gourley DR, Eoff JC. Complete review for pharmacy. In: Anti-infective agents. 10th edition. American Pharmacists Association, Washington DC; 2012. p. 788-92.

Dalgıç N, İnce E. Sistemik etkili antifungal ilaçlar. Klinik Pediatri. 2005;4:90-8.

Ashley ESD, Lewis R, Lewis JS, et al. Pharmacology of systemic antifungal agents. Clin Infect Dis. 2006;43:S28–39.

Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 2013;73:919-34.

Uptodate drug reference. https://www.uptodate.com access date 10.07.2018.

Stiller RL, Bennett JE, Scholer HJ, et al. Correlation of In vitro susceptibility test-results with in vivo response-flucytosine therapy in a systemic candidiasis model. J Infect Dis. 1983;147:1070-7.

Lepesheva GI, Waterman MR. Structural basis for conservation in the CYP51 family. Bba-Proteins Proteom. 2011;1814:88-93.

Sheng C, Zhang W. New lead structures in antifungal drug discovery. Curr Med Chem. 2011;18:733-66.

Wang E-j, Lew K, Casciano CN, et al. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Ch. 2002;46:160-5.

Dvorak Z. Drug–drug interactions by azole antifungals: Beyond a dogma of CYP3A4 enzyme activity inhibition. Toxicol Lett. 2011;202:129-32.

Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug Information Handbook. 20th edition. Lexicomp, Ohio, 2011.

Dıpıro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Invasive Fungal Infectious. In: Pharmacotherapy A pathophysiologic Approach. 8th edition. Mc Graw Hill, New York; 2008. p. 2073-105.

McKeage K. Posaconazole: A Review of the gastro-resistant tablet and intravenous solution in invasive fungal infections. Drugs. 2015;75:397406.

Lorand T, Kocsis B. Recent advances in antifungal agents. Mini-Rev Med Chem. 2007;7:900-11. 28. Sucher AJ, Chahine EB, Balcer HE. Echinocandins: The newest class of antifungals. Ann Pharmacother. 2009;43:1647-57.

Mukherjee P, Sheehan D, Puzniak L, et al. Echinocandins: Are they all the same? J Chemotherapy. 2011;23:319-25.

Petrikkos G, Skiada A. Recent advances in antifungal chemotherapy. Int J Antimicrob Ag. 2007;30:108-17.

Gershkovich P, Wasan EK, Lin M, et al. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. J Antimicrob Chemoth. 2009;64:101-8.

Pfaller MA, Messer SA, Rhomberg PR, et al. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin-and azole-resistant isolates. J Antimicrob Chemoth. 2016;71:2868-73.
Medicine Science-Cover
  • ISSN: 2147-0634
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 2012
  • Yayıncı: Effect Publishing Agency ( EPA )